Effects of recombinant human GM-CSF on secondary infection and prognosis in the immunoparalysis of sepsis

Effect of recombinant human GM-CSF on neutrophil extracellular traps and autophagy of polymorphonuclear and the prognosis of sepsis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042925

Enrollment

Unknown

Registered

2021-01-31

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

control group:non

thearpy group:rhGM-CSF

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Selected patients must meet all the below criteria: 1. aged between 18 and 85 years; 2. can be diagnosed as sepsis according to the "sepsis-3", and be charged in an intensive care unit; 3. the expression of HLA-DR in monocytes are less than 8000 cites/cell.

Exclusion criteria

Exclusion criteria: Selected patients must without one of the below criteria: 1. have accepted the therapy of GM-CSF or G-CSF before being chosen; 2. be allergic to GM-CSF; 3. have an immune dysfunctional complication, such as connective tissue disease, acquired immune deficiency syndrome, anti-rejection of transplants and so on; 4. be with an uncontrolled malignant tumor or pregnant; 5. have other reasons that are not suitable for clinical trials.

Design outcomes

Primary

Measure	Time frame
Incidence of secondary infection;28-day survival rate;ICU hospitalization days;SIC/DIC score;	—

Countries

China

Contacts

Public ContactTu Fuquan

Fujian Medical University Union Hospital

tfq_xhem@163.com+86 15679793082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026